Brigatinib for treating ALK-positive non-small-cell lung cancer after crizotinib [ID1328]: A Single Technology Appraisal

Ed Griffin; Max Barnish; David Packman; Helen Coelho; Justin Matthews; Sophie Dodman; Sophie Robinson; Adam Dangoor; Nicole Dorey; Martin Hoyle

Brigatinib for treating ALK-positive non-small-cell lung cancer after crizotinib [ID1328]: A Single Technology Appraisal

Ed Griffin, Max Barnish, David Packman, Helen Coelho, Justin Matthews, Sophie Dodman, Sophie Robinson, Adam Dangoor, Nicole Dorey, Martin Hoyle

Research output: Book/Report › Commissioned report

Original language	English
Publisher	University of Exeter
Commissioning body	National Institute for Health and Care Excellence (NICE)
Number of pages	189
Publication status	Published - 2018
Externally published	Yes

Access to Document

https://njl-admin.nihr.ac.uk/document/download/2021384Licence: Other

Cite this

@book{c31ec5f34a8d46cda69af13d562c53c7,

title = "Brigatinib for treating ALK-positive non-small-cell lung cancer after crizotinib [ID1328]: A Single Technology Appraisal",

author = "Ed Griffin and Max Barnish and David Packman and Helen Coelho and Justin Matthews and Sophie Dodman and Sophie Robinson and Adam Dangoor and Nicole Dorey and Martin Hoyle",

year = "2018",

language = "English",

publisher = "University of Exeter",

}

TY - BOOK

T1 - Brigatinib for treating ALK-positive non-small-cell lung cancer after crizotinib [ID1328]

T2 - A Single Technology Appraisal

AU - Griffin, Ed

AU - Barnish, Max

AU - Packman, David

AU - Coelho, Helen

AU - Matthews, Justin

AU - Dodman, Sophie

AU - Robinson, Sophie

AU - Dangoor, Adam

AU - Dorey, Nicole

AU - Hoyle, Martin

PY - 2018

Y1 - 2018

M3 - Commissioned report

BT - Brigatinib for treating ALK-positive non-small-cell lung cancer after crizotinib [ID1328]

PB - University of Exeter

ER -